Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth ...

BioMarin Pharmaceutical (BMRN) closed the last trading session at $70.49, gaining 10.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) is anticipated to release its earnings data before the market opens on Thursday, February 27th. Analysts expect BioMarin Pharmaceutical to post ...

On Wednesday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported fourth-quarter adjusted EPS of 92 cents, up from 49 cents reported a year ago, beating the consensus of 53 cents. The company ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

BioMarin Pharmaceutical BMRN is scheduled to report fourth-quarter and full-year 2024 earnings on Feb. 19, after market close. In the last reported quarter, BMRN’s earnings beat estimates by 16.67%.

Oppenheimer upgraded BioMarin (BMRN) to Outperform from Perform with a $98 price target BioMarin reported strong Q4 results and Oppenheimer ...

BioMarin is amassing a portfolio of genetic-disease therapeutics, making historical comparisons with Genzyme (acquired by Sanofi) difficult to avoid. Commercialization and research and development ...

Smartleaf Asset Management LLC grew its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 111.2% in the 4th quarter, according to the company in its most recent 13F ...